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Abstract 
Background: Adherence to Antiretroviral Therapy is the most important determinant of 
survival for people living with Human Immunodeficiency Virus / Acquired Immunodeficiency 
Syndrome and is a major tool for optimal virologic suppression as well as increased CD4+cell 
count. 
Objective: The objective of this study was to assess Anti Retro Viral Therapy adherence and 
associated factors among adult People Living with Human Immunodeficiency Virus on Highly 
Active Antiretroviral treatment in Teppi health center, Teppi town, South West Ethiopia, 2015.   
Methods: Institution based cross-sectional study was used to assess Anti Retro Viral therapy 
adherence and associated factors. A total of 381 patients on Highly Active Antiretroviral 
treatment selected by simple random sampling technique from Adult Antiretroviral treatment 
clinic were included in the study. A structured and standard questionnaire adapted from Adult 
AACTG was used. EpiInfo7 and SPSSversion20 were used for data entry and data analysis 
respectively. Descriptive statistics were carried out then bivariate and multivariate logistic 
regressions were used to explore significant variables. Variables having p-value≤0.05 were 
considered as statistically significant.  
Results: The prevalence of adherence to antiretroviral treatment was 81.7% [95%CI 77.8, 
85.9]. Use of memory aid [AOR: 4.68, 95%CI :( 2.12, 10.36)], regimen change [AOR: 0.23, 
95%CI: (0.07, 0.74)], disclosure status [AOR: 9.59, 95%CI: (2.87, 16.86)] and belief on 
efficacy of HAART [AOR: 0.06, 95%CI: (0.01, 0.94) were factors significantly associated with 
adherence to antiretroviral treatment.  
Conclusion and recommendation: The prevalence of adherence to antiretroviral treatment 
was comparable with most of studies. The main factors associated with HAART adherence 
were HIV disclosure status, use of reminder aid, initial HAART regimen change and belief on 
efficacy of HAART. Interventions to promote adherence should focus on areas, such as 
encouraging disclosure status, promoting use of different memory aids, like alarm watches 
and mobile bells, continuous monitoring and follow up of patients clinical condition and drug 
related factors.  
Key words: Adherence; Antiretroviral treatment; People living with HIV/AIDS; Highly active 
antiretroviral treatment. 
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1. Introduction  
1.1. Back ground 
There are around 35 million people living with the Human Immunodeficiency Virus (HIV) 
globally. In the year 2013, there were about 31.8 million adults living with Human 
Immunodeficiency Virus / Acquired Immunodeficiency Syndrome (HIV/AIDS). In the same 
year, there were 2.1 million new infections (1.9 million were adults) and 1.5 million deaths 
including 1.3 million adults. Since the start of the epidemic, around 78 million people have 
become infected with Human Immunodeficiency Virus (HIV) and 39 million people have died 
of Acquired Immunodeficiency Syndrome (AIDS)-related illnesses. The Human 
Immunodeficiency Virus (HIV) pandemic remains the most serious of infectious disease 
challenges to public health(1).  
In 2013, there were 24.7 million people living with Human Immunodeficiency Virus (HIV) in 
sub-Saharan Africa which accounts 70.6% of global total of people living with Human 
immunodeficiency virus (PLWHIV). There were an estimated 1.5 million new Human 
immunodeficiency virus(HIV) infections in sub-Saharan Africa which accounts for almost 70% 
of the global total of new Human immunodeficiency virus(HIV) infections and 1.1million  
people died of Acquired Immunodeficiency Syndrome(AIDS) -related causes in 2013 (1). 
Ethiopia has one of the largest populations of Human immunodeficiency virus(HIV) infected 
people in the world, With an estimated 35 million people living with Human immunodeficiency 
virus (HIV)(1). The 2011 Demographic Health Survey  of Ethiopia estimated the national adult 
HIV(Human immunodeficiency virus) prevalence in Ethiopia to be 1.5%, with infection levels 
highest in the Gambella (6.5%) and Addis Ababa (5.2%) regions (2). In 2013, the estimated 
numbers of people living with Human immunodeficiency virus(HIV) in Ethiopia were 793,700 
people (3).  
Highly Active Antiretroviral Therapy was a breakthrough leading to the reduction of mortality 
and the improvement of quality of life of people living with Human immunodeficiency 
virus(HIV) and Acquired Immunodeficiency Syndrome(AIDS)(4). In 2013, 12.9 million people 
worldwide were on Anti Retro Viral Therapy(ART) and About 37% of all people living with 
Human immunodeficiency virus in sub-Saharan Africa were receiving Anti Retro Viral 
therapy(ART) by the end of 2013(1). In Ethiopia at the end of June 2013, 317,443 patients 
(70.3%) were on HAART out of the 439,301 patients who ever started on Highly active Anti 
Retro Viral Therapy(HAART) since 2003 (1, 5). 
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1.2. Statement of the problem  
Combination therapy known as Highly Active Antiretroviral treatment (HAART) become the 
standard of care for PLWHIV in 1995.Its introduction has transformed HIV infection in to 
chronic manageable disease, bringing major impact on the quality of life and the prospects for 
an extended survival in PLWHIV. Although provides these benefits, combination therapy puts 
extraordinary demands on an individual due to their often complicated regimens and side 
effects (6). 
Numerous reports documented the key to the above success of the new HAART are the 
ability and willingness of HIV-positive individuals to adhere to complex ARV regimens for the 
high degree of success with HAART in achieving undetectable HIV-1 RNA levels reported in 
clinical trials (i.e. 60-90%), but this has seldom been achieved in everyday practice (6, 7). 
Adherence to ART is a powerful predictor of survival for people living with HIV/AIDS and is 
critical for optimal virologic suppression as well as improved CD4 cell count. Patients were 
considered having good adherence if they reported taking ≥95% of their medication as 
prescribed.(8) 
The rate of adherence to ART is low among PLWHIV on HAART in different settings and 
remains to be the key programmatic challenge of ART in many countries of the world and 
ensuring adherence to ART is one of the key principles(9-11). 
A survey in Cuba among 847 interviewed individuals, 70.6% of whom self reported had good 
adherence where as in Australians ,out of 867(78.4%) survey respondents that were taking  
ART medication,39.1% of them reported problems taking ART. The study in Cameroon 
showed that, even though 73% of patients had good adherence after the first month on ART, 
but this proportion reduced to 61% after two years. Whereas ART and its correlates in Addis 
Ababa indicated that, among 431patients, 81.2% of them had good adherence by self report 
(12-16). However, patient loss to follow-up and ensuring adherence to ART regimens remain 
major challenges of the ART programme especially in some of the regions (3). 
Patient must be committed to and capable of adhering to complicated regimens and with high 
pill burden. Even in highly committed patients, adherence wanes over time, a phenomenon 
described as "pills fatigue" or treatment fatigue" can occur(7). 
Adherence to antiretroviral therapy is important for HIV-infected persons, because adherence 
is linked to the reduction of drug resistance, increase in CD4 cell count, higher rates of 
undetectable viral load, higher therapeutic success and decreased hospital days (17).  
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However, adherence is most complicated and dynamic issue affected by variety of factors that 
includes drug side effect, lack of treatment supporter, pill burden, substance abuse, non-
disclosure of HIV status, nutritional problems as well as transportation costs. The continued 
occurrence of new HIV infection, AIDS related morbidity and mortality, lost to follow up, 
defaulter and treatment failure might be the consequences of lack of adherence(7). 
Hence, the government of Ethiopia also accepted and implementing the consolidated ART 
guideline adapted by WHO in 2013 that contains the revised ART eligibility criteria (cd4<500 
and B+ option) which increases ART uptake that needs adherence and its influencing factors 
that will become a challenge in different health settings particularly in primary health care 
setting where previously no research conducted on adherence and its influencing factors. 
Since there is no enough data on ART adherence and associated factors in primary health 
care settings in Ethiopia, specifically no research conducted in the current study setting(8).  
Therefore, the current study and its findings  provide information on level of adherence to ART 
and associated factors that result in adherence and as well as helps: program planners, 
groups developing guidance on care and support for PLWHIV, service providers and networks 
of PLWHIV in the study area to understand and address association of level of ART 
adherence with various factors which are useful in developing evidence based implementation 
that are carried out to address ART adherence specially at health center level.    
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1.3. Literature Review  
1.3.1. The level of HAART adherence: adherence to HAART is an important determinant of 
treatment success and reduction of development of drug resistance. A study in different parts 
of the world indicates that the level of HAART adherence is less than 95% (12, 18, 19). 
 The study conducted in Missouri (USA) which assessed base line predictors of ART 
adherence measured by EDM indicated that, of the 204 participants 180 and 168 participants 
had complete adherence data at 12 and 24 weeks respectively(20). Whereas cross-sectional 
study conducted in Brazil, A total of 1972 patients under ART from 60 health Services sites 
were interviewed and adherence prevalence estimate was 75.05%(18). Similar study 
conducted on HIV-infected adults receiving free antiretroviral therapy (ART) in two project 
sites of China’s Comprehensive AIDS Response program , A total of 181 patients participated 
in the study and 81.8% of them reported  >95% adherence  three days prior to interview(21). 
Adherence to ART in sub-Saharan Africa and north America in which 31 studies from north 
America and 27 studies from sub-Saharan Africa were included ,reported similar thresh holds 
for adherence monitoring. Accordingly, a pooled analysis of the North American studies 
indicated that, 55% of the population achieving adequate level of adherence while a pooled 
analysis of sub-Saharan Africa studies showed that, 77% had adequate level of adherence.  
Where as a Meta analysis for adherence to HAART which included 84 observational studies 
conducted across 20 countries indicated that, the average rate of reporting ≥90% adherent to 
HAART is 62%(19, 22). 
A Case- control study conducted on adherence to ART among adult PLWHIV in Tanzania, a 
total of 79 cases and 237 controls matched by age and sex were studied. A high Proportion of 
cases and controls (77.2% and 84.8%) had good knowledge of ART benefits, adherence and 
eligibility. Adherence to ART by adult patients attending HIV/AIDS clinic at Kenyan tertiary 
health institution in which 384 respondents were participated 93.5% of the participants adhere 
to clinic appointments but only 43.2% adhere to taking the drugs as per time schedule(23, 
24). 
 Anti retroviral therapy adherence and its correlates in Addis Ababa, Ethiopia in which 431 
patients on HAART responded that 81.2% of patients were ≥95% adherent by self report in 
the week before the interview. similar study was carried out at Yirgalem Hospital, to assess 
factors associated with adherence among AIDS patients showed, Prevalence of adherence in 
the week before interview was 74.2% (12, 16). 
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Institution-based cross-sectional study was conducted at 6 health centers in South Gondar 
Zone in which 647 HIV patients aged ≥18 years and were on ART for more than one month 
was included in the study, Out of the 647 ART users 552(85.3%) had reportedly taken 95% or 
higher of their prescribed antiretroviral drugs in the month before the interview, of these 
313(56.7%) were females and 239(43.3%) were males (25). 
1.3.2. The factors for adherence: adherence to ART is an important concern relating to HIV 
management in different setting and needs to be addressed with more patient oriented 
intervention (26-28). 
Age, travel time to ART centers, history of illegal drug use and adverse effects were all 
independently and negatively associated with HAART adherence(29). 
Mode of HIV exposure, ART regimen, time on ART and frequency of adherence 
measurement were significantly associated with HAART adherence(30). 
 According to the study conducted in china, patients’ knowledge about side effects, belief 
towards ART, having developed reminder tools of taking medication and patient’ trust and 
confidence in his/her care provider were independently associated with HAART 
adherence(21).   
In sub Saharan Africa, malnutrition and food insecurity have emerged as a major obstacles to 
ART adherence(31). 
As cross-sectional study conducted among a total of 250 patients on HAART on Adherence to 
highly active antiretroviral therapy and its challenges in Keffi, Nigeria, Patient’s educational 
level, marital status and occupation were found to be significantly associated with adherence 
to HAART (32). 
A longitudinal observational study in Mambwa district, Zambia, showed that, 59.9% were fully 
adherent to the treatment. The full adherence was associated with being female and having a 
spouse who were also on ART(13). 
An observational analysis in Uganda and Zimbabwe showed that the most common reasons 
for missing doses were: Forgot 1072 (N, 50%), away from home 953 (N, 45%), ran out of 
drugs 678 (N, 32%), too busy 425 (N, 20%), sick 380 (N, 18%), avoiding side effects 282 (N, 
13%), change in routine 248 (N, 12%), slept through dose 235 (N, 11%), and too many pills 
187 (N, 9%)(33). 
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Various studies conducted in our country to find out factors which affects adherence to 
HAART, 
According to the  study conducted in Nekemte Hospital, educational status of the participants, 
concomitantly used medication, family and social support, belief in efficacy of HAART, 
following clinical appointment regularly, using reminding aid, having access to medical care 
regardless of place and time, improvement upon taking HAART, relationship with health 
professionals, history of substance use and continuing to take the medication if the disease 
condition is worsened were associated with medication adherence of the patients(34). 
 A study conducted on adherence to Antiretroviral Treatment and Associated Factors in south 
Gondar zone among 647 patients living with HIV/AIDS, indicated that; Use of memory aid, 
satisfaction with clinical change, fitness of single drug regimen with daily routine and 
experience of drug side effects were factors Significantly associated with adherence to 
antiretroviral treatment(25).  
Disclosure of HIV status, social support(emotional and practical), use of reminder aids, 
responsibility for raising children, improved health on ART, and receiving education and 
counseling were associated with adherence to HAART(35). 
According to the study conducted in Yirgalem hospital, absence of symptoms in the past 
month, distance of residence, and absence of dependents were all significantly associated 
with HAART adherence(12)  
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1.3.3. Conceptual Frame Work  
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Figure-1: Conceptual frame work to assess factors affecting ART adherence (12, 13, 23, 25, 
28, 31, 32). 
 
 
 
 
1.4. JUSTIFICATION 
Patient adherence to ARV combination therapy is a critical component of successful treatment 
outcome. While combination therapy is known to be effective in slowing disease progression, 
the long-term benefit of these therapies can only be sustained if resistance strains of HIV do 
not emerge among factors that can result in the emergency of resistance(7).  
The government of Ethiopia also accepted and implementing the consolidated ART guideline 
adapted by WHO in 2013 that contains the revised ART eligibility criteria (cd4<500 and B+ 
option) which increases ART uptake that needs adherence and its influencing factors that 
become a challenge in different health settings particularly in primary health care setting 
where previously no research conducted on adherence and its influencing factors(8). 
Since there is no enough data on ART adherence and associated factors in primary health 
care settings in Ethiopia, specifically no research conducted in the current study setting.  
Evidence shows that the numbers of people who are lost to follow up and dropout from 
treatment increasing from time to time as well as their level of ART adherence is not clearly 
known and the reasons why patients lost and dropout from treatment are not known. 
 The current study and its findings provided information on level of adherence to ART and 
associated factors that result in adherence. 
 The findings of this study will help: program planners, groups developing guidance on care 
and support for PLWHIV, service providers and networks of PLWHIV in the study area to 
understand and address association of level of ART adherence with various factors that are 
useful in developing evidence based implementation that are carried out to address ART 
adherence specially at health center level.     
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2. Objectives  
2.1. General objective 
The aim of this study was to asses ART adherence and associated factors among adult 
patients living with HIV/AIDS on highly active anti-retroviral treatment in Teppi health center, 
Teppi town, SNNPR , south west Ethiopia, 2015. 
2.2. Specific objectives 
 To determine adherence to antiretroviral therapy. 
 To identify factors associated with adherence of antiretroviral therapy. 
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3. Methods and materials 
3.1. Study design  
 Institution based cross – sectional study design was employed. 
3.2 .Study area and period  
 The study was conducted from May to June, 2015 at Teppi health center HIV care clinic. It is 
located in Teppi town administration, SNNPR, which is far from about 610 km south west of 
Addis Ababa, capital city of Ethiopia and 885 km far from Awassa, regional city.  According to 
the 2007 population and housing census report, the total population size of Teppi town was 
30,781. Currently Teppi town has one primary Hospital, which established a year back and 
one government Health Center and six medium clinics. The HIV care service of the Health 
center was initiated in 2006 and has three clinics: Adult ART clinic, Pediatric ART clinic and 
VCT clinic. The adult ART clinic has 1 Health officers, 2 BSc and 2 Diploma nurses providing 
ART services and 2 data clerks, 1 case manager and 2 adherence supporters. There were 
about 2239 ever enrolled, 1260 ever started and 1000 adults were currently on ART(15). 
3.3. Source population  
All adult PLWHIV/AIDS on HAART in Teppi town 
3.4. Study population  
Adult PLWHIV/AIDS on HAART who has follow up in Teppi health center  
3.5. Inclusion and Exclusion criteria  
All patients on HAART for at least a month in Teppi health center and who were on follow up 
and aged above 18 years were included. However, all adult patients on HAART who were 
seriously ill and unable to respond were excluded. 
3.6. Sample size determination and sampling procedure 
Epi info 7 stat cal was used to calculate the number of study participants by taking confidence 
level of 95% and marginal error of  5% for prevalence while for factors associated with ART 
adherence (unexposed :exposed(1:1). 
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Table-1: Sample size determination for prevalence and associated factors of ART adherence 
among adult PLWHA in Teppi health center, south west Ethiopia, 2015. 
Prevalence and factors  P (%) n Remark 
Adherence prevalence 74.2 227  
Pill burden Power (80%) 
Confidence level (95%) 
Odds ratio(2.49) 
346  
prevalence of adherence and proportion of associated factors(12, 25). 
Where: 
n - Number of adults on HAART 
p - Proportion of adherence 
Among all ‘n’s, the highest number was taken as the total sample size of the study subjects 
for both prevalence and factors associated with ART adherence which was 346. The final 
sample size was 381, after adding 10% non response rate. 
3.6.1 Sampling procedure 
Simple random sampling was used to select the study subjects after obtaining a list from ART 
registration book. Then, lottery method was used to select study participants. 
3.7. Study Variables 
 Dependent Variable 
Patient adherence to HAART (yes/no)  
Independent variables 
Socio – demographic variables: Age, Sex, Religion, Residence, Ethnicity, 
Educational Level, Current Marital status, occupational status and distance to ART 
center.  
Behavioral related factors: Substance Abuse (Alcohol, chat and smoking). 
Patient and physician Relationship:  Client satisfaction with ART service 
Psycho-social factors: Disclosure status, Emotional support, Practical support, Belief 
in efficacy of medication and Reminder tool use. 
Medication factors: Number of pills prescribed, Medication adverse effect, Duration 
on ART, Type of ART regimen, and ART regimen change. 
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Nutritional factors: Nutritional status. 
Clinical factors: WHO staging. 
3.8. Operational definition 
Adherent: If an individual is taking ≥95% their prescribed ART drugs in the month before the 
interview(8). 
Non-adherent: If an individual is taking <95% their prescribed ART drugs in the month before 
the interview(8). 
Poor nutritional status: adult patients having BMI < 18.5kg/m2 for their weight over height 
square and MUAC <21cm were considered as a poor level of nutritional status(36). 
Good nutritional status: adult patients having BMI ≥18.5kg/m2 for their weight over height 
square and MUAC ≥21cm were considered as a poor level of nutritional status(36). 
3.9. Data collection instruments and procedures 
 A structured and standardized interviewer--administered questionnaires adapted from 
AACTG and measuring ART adherence by questioning about the number of doses missed 
during the past one month, which was changed quantitatively into a percentage 
adherence(37). Measuring instruments including weighing scale, centimeter and height 
measuring board were used to assess the nutritional status of PLWHIV on HAART. 
3.10. Data collection procedures 
To secure privacy and maintain the confidentiality of the study participants, 2diploma nurses 
who have the experience of delivering HIV care and ART treatment outside ART unit were 
used as data collectors and one health officer as supervisors were trained for 2 days with the 
aim of standardizing the data collection instrument among the data collectors and providing 
them with the basic skill of communicating with the study participants. Before the actual data 
collection carried out, a pre-test of the instrument and the procedure was carried out and 
corrective action was taken. Dose adherence was assessed by asking participants to report 
on how many days they had missed taking all or some their doses during the previous one 
month.  
 Nutritional status measurement:  
Measurement of weight: measurement of weight was conducted using a standard beam 
balance. During that time, the scale pointer was checked at zero, the person was required to 
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dress in light clothes and take off shoes. The individual was stand straighter and unassisted 
on the center of the balance plat form. The measurement was recorded to the nearest 0.1kg. 
Measurement of height: it was done using standard scale. At that time the person was 
required to remove his/her shoes, stand straight, looking straight in a horizontal plane with the 
feet together and knees straight, as well as the heels, buttocks, shoulder blades and the back 
the head touched against the wall. It was recorded to the nearest 0.1cm. 
MUAC: was measured on the mid way between the tip of shoulder and tip of elbow of the left 
upper arm by using centimeter. It was recorded to the nearest 0.5cm  
3.11. Data quality control measures 
To ensure data quality, a pre-tested standard questionnaire was carried out with 5% of 
sample size out of the study area, mizzen health center, which renders ART services. 
Training on the purpose of the research, on how to approach study subjects and how to use 
the questionnaire was given for two days for data collectors and supervisors. The collected 
data was checked out for completeness, accuracy and clarity by the principal investigator and 
supervisors. This quality checking was done daily after data collection and correction was 
made before the next data collection measure. Data clean up and cross-checking was done 
before analysis. 
3.12. Data processing and analysis 
Data collected through a structured interviewer administered questionnaire was entered in to 
Epi Info version7 and exported to SPSS version 20 for analysis. Analysis of variables was 
made using descriptive statistics (basic summaries of the patient characteristics), Variables 
which had a p-value of < 0.2 on binary logistic regression was fitted in to a multivariate logistic 
regression model to identify the independent contribution of each variable for the ART 
adherence status of adults. 
 Bivariate logistic analysis to look into the association between exposure variable and 
adherence to ART and multi-variate logistic regression analysis to adjust values of the 
dependent variable for the influence of the likelihood of the confounding variables (with a p-
value of ≤0.05 was considered statistically significant). Odds ratios (OR) and their 95%CI was 
used to look into the association between dependent and independent variables.     
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3.13. Ethical consideration  
To conduct this research project Ethical approval was obtained from the Ethical Review Board 
of University of Gondar, College of Medicine and health sciences, school of medicine. Then 
official letters was submitted to Teppi town health unit and then a written permission was 
obtained from Teppi town health unit as well from respective health institution in the town. In, 
addition letters of support from organization for social service for AIDS (Char Ethiopia, an 
association of PLWHIV in Teppi town administration that works on the rights and wellbeing of 
member of PLWHIV) was taken before commencing data collection process. During data 
collection process the data collectors informed each study participant about the purpose and 
anticipated benefits of research project and the study participants were also informed on their 
full right to refuse, withdraw or completely reject part or all of their part in the study and they 
were assured that their treatment and other benefits they gain from the health center or other 
organization was not influenced by their participation in the study. Finally, they were provided 
with informed consent to participate or not participate in the study. 
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4. Results  
4.1. Socio demographic characteristics 
From a selected participant, 361 were participated in a study with a response rate of 94.75%. 
Among study participants 199(55.1%) were females. The mean age of the respondents was 
34.7±8.2s. Concerning ethnicity, majority of the respondents 120(33.2%) were Amhara and 
174(48.2%) of the respondents were Orthodox in religion. With regard to educational status, 
142(39.3%) were attended primary school followed by, 96(26.6%) who are able to read and 
write. most of the respondents, 185(51.2%) travels a distance of less than 10 kilometer to 
reach to ART clinic (Table 2).  
4.2 Psychosocial related factors 
Among 361 respondents, 262(72.6%) were disclosed their HIV status to others and 
212(58.7%) had got emotional support, while 95 respondent had got practical support. among 
a total respondents majority of them, 204(56.5%) agreed on efficacy of ART in preventing HIV 
disease progression (Table 3).  
4.3 Patient and health care provider related factors 
Among all respondents, 130(36%), 129(35.8%), 86(23.8%) and 16(4.4%) were satisfied, 
strongly satisfied, somewhat satisfied and Dissatisfied with the provided service respectively.  
4.4 Behavior related factors of the respondent 
Most of the respondents, 209(57.8%) were ever users of alcohol and 75(20.8%) were ever 
chat chewers where as 38(10.5%) were active alcohol users (Figure 2).  
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Table-2: Socio demographic characteristics of respondents among adult PLWHA on HAART 
in Teppi health center, Ethiopia, 2015(n=361). 
Study variables category Frequency Percent 
Place of residence Urban 195 54 
Rural 166 46 
 
Age in years 
 
18-24 19 5.2 
25-34 176 48.8 
35-44 134 37.1 
≥45 32 8.9 
Sex 
 
Female 199 55.1 
Male 162 44.9 
Religion  
 
Orthodox 174 48.2 
Muslim 96 26.6 
Protestant 91 25.2 
Ethnicity  
 
Amhara      120 33.2 
Tigre  82 22.7 
Dewuro  48 13.3 
Kaffa  66 18.3 
Othersa  45 12.5 
Marital Status    Single  42 12 
Married         290 80 
Divorced  22 6 
Widowed      7 2 
Educational status Un able to read and write  19 5.3 
Able to read and write  96 26.6 
Grade1-8         142 39.3 
Grade9-12                    67 18.6 
College and above 37 10.2 
Occupation 
 
 
 
 
Farmer 55 15.2 
Housewife 116 32.1 
Merchant  75 20.8 
Employee                84 33.3 
*Others  31 8.6 
Distance to ART 
clinic in kilometer 
≤10 185 51.2 
>10 176 48.8 
 
Others
a
: Sheka,Gurage,Sheko,Hadiya,Kambata,Wolaita and Oromo  
* Others: have no job, students, dayily laborer   
 
 
 
 
 
17 
 
Table3: Psychosocial related factors of respondents among adult PLWHA on ART in Teppi 
health center, Ethiopia, 2015(n=361) 
Study variables category Frequency  Percent  
HIV status 
disclosure 
Yes 262 72.6 
No 99 27.4 
Emotional support Yes 212 58.7 
No 149 41.3 
Practical support Yes 95 26.3 
No 266 73.7 
Agreement in 
belief on 
effectiveness of 
HAART 
Disagree 7 2 
Somewhat agree 65 18 
Agree 204 56.5 
Strongly agree 85 23.5 
  
 
 
 
Figure 2: Behavioral characteristics of respondents among adult PLWHA on ART in Teppi 
health center, Ethiopia, 2015(n=361) 
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4.5. Medication (treatment) related factors 
 Among total respondents, 231(64%) were on HAART for more than twenty four months of 
which majority of them started on TDF+3TC+EFV,89(24.7%) followed by 
d4T+3TC+NVP,88(24.4%) as their original regimen. original ART regimen was changed for 
173 respondents mainly to TDF+3TC+EFV,97(56%) followed by AZT+3TC+NVP,36(20.8%). 
The main reason for regimen change was drug side effect. Currently, out of 361 respondents, 
186(51.5%) were on TDF+3TC+EFV. Among the total respondents, 96(26.6%) had missed 
taking some of their prescribed medications doses. The most common reasons for missed 
pills were forgot, away from home, lack of transportation cost, fear of HIV disclosure status 
and lack of food to take with drug(Table 4). 
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Table-4: Medication factors of respondents among adult PLWHA on ART in Teppi health 
center, Ethiopia, 2015(n=361) 
 
                   Others
c: progress of illness, alcohol use 
 
Study Variables category Frequency percent 
Duration on ART <6 month  9 2.5 
6-12 month 42 11.6 
12-18 month 51 14.1 
18-24 month 28 7.8 
>24 month 231 64 
Original ART regimen d4t+3tc+efv 81 22.4 
d4t+3tc+nvp 88 24.4 
Azt+3tc+nvp 73 20.2 
Azt+3tc+efv 27 7.5 
Tdf+3tc+efv 89 24.7 
Tdf+3tc+nvp 3 0.8 
Change of original regimen Yes 173 47.9 
No 188 52.1 
Changed to regimen Azt+3tc+nvp 36 20.8 
Azt+3tc+efv 15 8.7 
Tdf+3tc+efv 97 56 
Tdf+3tc+nvp  25 14.5 
Reason for change Side effect 171 98.8 
Other 2 1.2 
Current regimen 
 
 
Azt+3tc+nvp 103 28.5 
Azt+3tc+efv 44 12.2 
Tdf+3tc+efv 186 51.5 
Tdf+3tc+nvp 28 7.8 
Follow up time for ART Monthly 361 100 
Frequency of daily dose Once 188 52.1 
Twice 173 47.9 
Missed pills Yes 96 26.6 
No 265 73.4 
Reason for missed pills(n=96) pill burden 5 5.2 
fear of side effect 6 6.3 
lack of food to take with drug 9 9.4 
Felt well 3 3.1 
fear of disclosure 10 10.5 
Away from home 15 15.6 
Lack of transportation cost 13 13.5 
Forgot 32 33.3 
othersc 3 3.1 
Use of reminder tool Yes 188 52.1 
No 173 47.9 
20 
 
4.6 Nutritional related factors 
Majority of respondents, 278(77%) had good nutritional status (Table 5). 
Table-5: Nutritional related factors of respondents among adult PLWHA on ART in Teppi 
health center, Ethiopia, 2015 
Study variables category frequency Percent 
Nutritional status 
by BMI and 
MUAC(n=361) 
poor 83 23 
good 278 77 
 
4.7 Prevalence of adherence 
 Among the respondents, 295(81.7%) were to HAART(Figure3). 
 
 
Figure 3: adherence to HAART among adult PLWHA in Teppi health center, Ethiopia, 
2015(n=361)  
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4.8 Factors associated with HAART adherence 
Factors that were related to adherence of HAART among the respondent were analyzed by 
using binary logistic to saw the individual effect after fitting to bi-variable logistic regression. 
During crud analysis of bi-variable, HIV disclosure status, emotional support, practical 
support, nutritional status, ART regimen change, use of reminder tool, current WHO staging, 
adverse effect of medication, patient satisfaction with service provided, and belief on efficacy 
of HAART were statically significant. But when those variables were fitted in to multivariable 
analysis, HIV disclosure status of the respondents, reminder tool usage to take the 
medications, change of initial HAART regimen and belief on efficacy of HAART were the 
independent predictors of adherence. 
The odds of being adherent to HAART among disclose their HIV status were 9.6 times higher 
when compared with non disclosed one (AOR = 9.59, 95%CI (2.87, 16.86)). 
Those who had initial regimen change were 0.2 times less likely to be adherent when 
compared to those whose regimen were not change (AOR=0.230., 95%cI (0.07, 0.74)). Using 
reminder tools to take their HAART pills were very important for adherence. Those who used 
any reminder tool were 4.7 times higher when it was compared to non user to be adherent 
(AOR: 4.68, 95 %( 2.12, 10.36)) and among respondents who disagree on efficacy of HAART 
in preventing disease progression were 94% less likely to be adherent when compared with 
those having strong belief as shown in the table below (Table 6). 
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Table 6: Binary logistic and multivariable logistic regression result for HAART adherence 
among adult PLWHA in Teppi health center. 2015(n=361).  
Study 
variables 
category Adherence 
condition 
COR, 95%CI AOR, 95%CI 
yes no 
Age in 
years 
18 – 24 15 4 1.05(0.26, 4.19) 1.22(0.17, 8.76) 
25 – 34 142 34 1.21(0.48, 3.04) 1.08(0.30, 3.86) 
35 – 44 112 22 1.43(0.55, 3.70) 2.04(0.56, 7.49) 
45+ 26 6 1 1 
Sex Male  136 26 1.22(0.71, 2.10) 0.40(0.14, 1.16) 
Female 159 40 1 1 
Residence  Urban  164 31 1.25(0.83, 2.41) 3.45(0,66, 18.14) 
Rural  131 35 1 1 
 marital 
status 
 
 
Single 35 7 1.00(0.10, 9.84) 6.09(0.29, 13.1) 
Married 235 55 0.68(0.08, 5.77) 3.63(0.22, 60.51) 
Divorced 19 3 1.67(0.13, 21.73) 11.36(0.39, 33) 
widowed 6 1 1 1 
Religion  Orthodox 146 28 1 1 
Muslim 79 17 0.85(0.44, 1.66) 0.67(0.27, 1.62) 
protestant 70 21 0.58(0.31, 1.08) 0.55(0.23, 1.31) 
Educationa
l status 
Unable to 
read & write 
12 7 1 1 
Able to read 
& write 
81 15 3.15(1.07, 9.30) 5.09(1.00, 25.00) 
Grade1-8 118 24 2.87(1.02, 8.04) 4.32(0.93, 20.10) 
Grade9-12 54 13 2.42(0.79, 7.36) 1.67(0.29, 9.39) 
College & 
above 
307 7 2.5(0.72, 8.67) 1.52(0.19, 12.41) 
Occupation
al status 
Farmer 49 6 1 1 
Housewife 87 29 0.35(0.14, 0.90) 7.20(0.93, 36.31) 
Merchant 67 8 1.03(0.33, 3.15) 3.53(0.66, 18.92) 
employees 69 15 0.56(0.20, 1.55) 3.13 (0.55,17.70) 
Others  23 8 0.42(0.13, 1.39) 7.88 (0.99, 57.08) 
Distance to 
ART center 
in 
kilometer 
≤10 155 30 1.33(0.78,2.27) 0.98(0.19, 4.97) 
>10 140 36 1 1 
HIV 
disclosure 
status 
yes 226 36 *2.73(1.33,4.06) **9.59(2.87,16.86) 
No 69 30 1 1 
Emotional 
support 
Yes 181 31 *1.54(0.90, 2.64) 0.44(0.15, 1.25) 
No 114 35 1 1 
Practical 
support 
Yes 83 12 *1.76(0.89, 3.46) 0.98(0.35, 2.71) 
No  212 54 1 1 
Nutritional Poor  60 23 1 1 
23 
 
status Good  35 43 *1.92(1.07, 3.44) 2.11(0.85,5.23) 
Current 
alcohol 
user 
Yes 30 8 1 1 
No 265 58 1.01(0.42, 2.41) 0.67(0.17, 2.62) 
Current 
cigarette 
smoker 
Yes 12 1 1 1 
No      283 65 0.36(0.05, 2.84) 0.44(0.04, 4.66) 
Current 
chat 
chewer 
Yes 15 5 1 1 
No 280 61 1.13(0.36, 3.48) 2.58(0.58, 11.56) 
ART 
regimen 
change 
Yes 129 44 *0.39(0.22, 0.68) **0.23(0.07,0.74) 
No 166 22 1 1 
Current 
ART 
regimen 
Azt+3tc+nvp 82 21 1.07(0.38, 2.96)  
Azt+3tc+efv 36 8 1.23(0.38, 4.01)  
Tdf+3tc+efv 155 31 1.36(0.51, 3.64)  
Tdf+3tc+nvp 22 6 1  
Number of 
pills 
prescribed 
30 155 33 1.11(0.55, 2.27) 1.08(0.39,2.98) 
60 83 20 0.89(0.41, 1.92) 0.73(0.23, 2.34) 
90 97 13 1 1 
Medication 
adverse 
effect 
Yes 76 25 1 1 
No  219 41 *1.76(1.00, 3.08) 1.94(0.88, 4.28) 
Use of 
reminder 
tool 
Yes 172 16 *4.37(2.38, 8.03) **4.68(2.12, 10.36) 
No 123 50 1 1 
Duration 
on ART 
<6month 7 2 1 1 
6-12month 36 6 2.11(0.34, 13.15) 3.97(0.30, 51.80) 
12-18month 46 5 2.63(0.43, 16.26) 2.03(0.1528.31) 
18-24month 24 4 1.71(0.26, 11.40) 3.99(0.25, 64.86) 
>24month 182 49 1.03(0.21, 5.14) 2.93(0.23, 32.64) 
Belief on 
efficacy of 
ART 
Disagree 3 4 *0.09(0.02, 0.46) 0.06(0.01, 0.94) 
Somewhat 
agree 
55 10 0.65(0.23, 1.71) 2.22(0.52, 9.49) 
Agree 161 43 *0.44(0.21, 0.96) 0.79(0.28, 2.22) 
Strongly  
agree 
76 9 1 1 
Satisfactio
n  
Dissatisfied  11 5 *0.43(0.14, 1.36) 1.28(0.07,24.13) 
Somewhat 
satisfied  
64 22 *0.57(0.29, 1.11) 0.53(0.15, 1.86) 
Satisfied  112 18 1.21(0.61, 2.39) 1.16(0.48, 2.81) 
Very satisfied  108 21 1 1 
Current 
WHO stage 
Stage one 4 1 2.63(0.27, 25.14)  
t-stage one 259 44 *3.86(2.04, 7.30)  
t-stage two 32 21 1 1 
*- statically significant at a p value < 0.2   ** - statically significant at p value < 0.05, 1 = reference  
Others = students, have no job, daily laborer  
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5. Discussion 
World Health Organization (WHO) recommends at least 95% of adherence to ART to avoid 
the emergence of drug resistant strains of HIV(38). Based on these facts, the importance of 
adhering to ART has been widely publicized and accepted as a critical element in the success 
of ART. However, many of the reported adherence rates are below what is recommended 
which does not guarantee for treatment success (12, 16, 19, 21). 
In this study, 81.7% [95CI 77.8, 85.9] of the patients had self-reported adherence of the 
prescribed doses in the month prior to the interview. This was in line with the study conducted 
in china (81.8%) , Addis Ababa (81.2%) and south Gondar zone (85.3%) but higher than 
study conducted in Brazil (75.05%) and yirgalem (74.2)(12, 16, 21, 25, 27).The improvement 
might be due to continuous efforts to strengthen the health system infrastructure, increase 
public awareness, involve community health extension workers, build staff capacity and step 
up the number of sectoral collaborations to prevent and control HIV/AIDS epidemic. 
Adherence is most complicated and dynamic issue affected by variety of factors that includes 
drug side effect, lack of treatment supporter, pill burden, substance abuse, non-disclosure of 
HIV status, nutritional problems as well as transportation costs. 
In our study the factors that affect adherence to HAART were HIV disclosure status, use of 
reminder tool to take the medications and change of initial HAART regimen and belief on 
efficacy of HAART. The odds of being adherent to HAART among disclose their HIV status 
were 9.6 times higher when compared with non disclosed one (AOR = 9.59, 95%CI (2.87, 
16.86)). This is supported by the study conducted in Tanzania and Gondar university 
hospital(31, 35) .This might be due to lack of discomfort to take in front of others. Those who 
had initial regimen change were 0.23 times less likely to be adherent when compared to those 
whose regimen were not changed (AOR=0.230., 95%cI (0.07, 0.74) which is similar with the 
study conducted in south Gondar zone(25). This might be due to increased pill burden, 
psychological impact of previous side effect and disease progression. Using reminder tools to 
take their HAART pills were very important for adherence. Those who used any reminder tool 
were 4.7 times higher when it was compared to non user to be adherent (AOR: 4.68, 95 %( 
2.12, 10.36)) which is supported by the study conducted in china, Nepal, Nigeria and south 
Gondar zone (21, 25, 29, 32). This might be due to fixing reminding time of drug intake, which 
decreases forgetfulness. Among respondents who disagree on efficacy of HAART in 
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preventing disease progression were 94% less likely to be adherent when compared with 
those having strong belief. This might be due to lack of information on HAART. 
  
The findings of this study must be interpreted in the light of its limitations. There is no gold 
standard for measuring adherence, and our measurement of adherence is based on PLWHA 
self-reports of missed doses which may be subject recall biases. Since the study is cross-
sectional and does not show cause-effect relationship.  
In most of the researches medication adverse effect and pill burden were factors associated 
with HAART adherence but in our study they were not statically significant. This might be due 
to introduction of B+ option which has fewer side effects and fixed combination of single daily 
dose. Since more than half of the study participants were on this regimen (Tdf+3tc+efv). 
6. Conclusion 
The prevalence of adherence to antiretroviral treatment was comparable with most studies. 
The main factors associated with HAART adherence were HIV disclosure status, use of 
reminder tool and initial HAART regimen change and belief on efficacy of HAART. 
7. Recommendation 
Based on the findings of the study the following points recommended to help in improving the 
level of HAART adherence. 
FMOH/NGO/Teppi health unit 
Provide reminder tool support for clients on HAART for those who have no access  
Health care providers 
Better to initiate and encourage disclosure status 
Encourage reminder tool usage 
Proper assessment of clinical and drug related factors before initiating HAART and on 
continuous follow up  
Adherence supporters 
To provide adherence support more effectively and continuously on disclosure status and 
reminder tool use 
Researchers 
To conduct further research by using biochemical testing (drug level monitoring) 
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9. Annexes  
Annex-I: participant information sheet (English version) 
Title of research project: Adherence to Anti retroviral Treatment and Associated Factors 
among Adult Patients Living with HIV/AIDS in Teppi Health Center, South West Ethiopia, 
2015.  
Name of principal investigator: Deneke Desta    
Name of advisors: 1. Mr. Ejigu Gebeye 
                                2. Dr Workagegnehu Hailu                                                                                               
Name of organization: University of Gondar, college of medicine and health science, 
department of internal medicine. 
 Introduction: This information sheet was prepared to explain the research project that you 
are asked to join by a group of research investigators. The major aim of this research project 
was to assess the level of ART adherence and associated factors among adult PLWHIV/AIDS 
who are on HAART in Teppi health center, Teppi town administration, 2015.           
Purpose: The purpose of this study was to assess the level of ART adherence and 
associated factors among adult PLWHIV/AIDS who are on ART in Teppi health center, Teppi 
town administration, 2015.  
 This study was primarily aimed to find HAART adherence level and the associated factors 
which affects ART adherence of adult People living with HIV/AIDS, develop action plans and 
to propose solutions by which the level of ART adherence can be increased or improved. 
Findings from this study will be used to assist in making recommendations for those who are 
responsible to design effective and appropriate measure for the improvement of patient 
adherence to ART, patient care with HIV/AIDS as well as prevention of opportunistic 
infections or promotion of the general well being of the patients.            
Procedure: this study used institution based cross-sectional study. 
Permission was processed from the University of Gondar and finally to the concerned health 
institution. 
Risk and or discomfort: 
There is no any risk or discomfort that you will face by participating in this research. Any 
personal information registered in registration books was not copied and transferred to other 
bodies. Every piece of information was kept confidentially. 
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Benefits 
There will be benefit for the patient living with HIV/AIDS on ART in Teppi health center by 
participating in this research. The results of the study will be used to implement the 
intervention and reveal out the problem related to ART non-adherence and provides the 
mechanisms on which the general health and wellbeing of the patient will be improved. This 
study will also used to reduce morbidity and mortality of patients related to combined effects 
of malnutrition and HIV/AIDS. 
Incentives/payment for participating: 
There was no any incentive or payment gained by taking part in this project. 
 Confidentiality: 
All personal identifiers and personal information was not taken. The information collected from 
this research project was kept confidential. Information was accessed by the researcher and 
research assistant only. 
Voluntariness 
You do not need to participate in the study if you do not want to. You have the right to with 
draw from the research study at any time. By not participating in the study no one was 
penalized and loss anything.  
Right to refusal or withdraw 
You have a full right to refuse from participating in this research and this will not affect you 
from getting any kind of treatment or PLWHA benefits from it. You have also a full right to with 
draw from this study at any time you want without losing any benefit from the project. 
Privacy: for the sake of privacy the interview will be conducted in a private room, with good 
lighting, no other person and in calm and quite environment. 
Duration: The interview may take a total duration with the range of 30-40 minutes. 
Compensation: during participation in the study there is no any compensation that was 
refunded for your time that we take during interview and taking measurements. 
Persons to contact: If you want to talk to someone about this study, if you feel you have not 
been treated properly, you are hurt by joining the study, if you have any question, you can 
contact:   Principal investigator: Deneke Desta: 0935663303 or 
                Advisors: Mr Ejigu Gebeye (mph, epidemiology and biostatics, university of Gondar)  
                Dr Workagegnehu Hailu (Department of internal medicine, university of Gondar)                                                                          
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Annex – II: consent form (English version) 
I the undersigned have been informed that the interview was conducted to gather information 
about adherence of ART. The result of the study will help the government, health facilities, 
and non-governmental organization involved in HIV/AIDS prevention, control and treatment. 
The result has also importance for the societies. I also agreed about the confidentiality of the 
respondents to be at a highest possible level.                                                                                        
Annex –III: English version Questionnaires 
University of Gondar College of medicine and health Sciences Department of internal 
medicine 
Code ____________________ 
Date_____________________ 
Interviewer name ---------------------------------signature-------------------------------- 
Supervisor name---------------------------------signature---------------------------------- 
 
 My name is ----------------------------------- and I am working as data collector in adherence 
among ART clients in this health center and you are also selected randomly to be asked. The 
purpose of this questionnaire is to collect data on the ART adherence and associated factors. 
The research will be beneficial to those who involved on HIV/AIDS care and support 
programs. 
Dear respondent: all of the information you give us was kept secured and confidentiality was 
maintained. Your honest participation and answers to the questionnaires was helped us in 
better understanding of the problem and to provide guidance on how to intervene within the 
study area. So would you willing to participate actively and honestly?. Thank you for being 
cooperative to answer for the questions provided. Contact person in need investigator.  
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1. socio-demographic characteristics 
s/no   Questions Response categories      skip 
Q101  Age -------------------------------------------------------(in years)   
Q102 Sex  Male------------------------------------------------------------1 
Female---------------------------------------------------------2 
 
Q103 Residence  Urban----------------------------------------------------------1 
Rural-----------------------------------------------------------2  
 
Q104 Religion  Orthodox------------------------------------------------------1 
Muslim---------------------------------------------------------2 
Protestant-----------------------------------------------------3 
Others(specify)----------------------------------------------4 
 
Q105 Ethnic group Amhara--------------------------------------------------------1 
Tigire ----------------------------------------------------------2 
Dewuro--------------------------------------------------------3 
kaffa -----------------------------------------------------------4 
Others(specify)----------------------------------------------5 
 
Q106 
 
 
 
Current marital status Single----------------------------------------------------------1 
Married -------------------------------------------------------2 
Divorced------------------------------------------------------3 
 Widowed-----------------------------------------------------4 
 
Q107 Educational status unable to read and write----------------------------------1 
able to Read and write------------------------------------2 
Grade 1-8-----------------------------------------------------3 
Grade 9-12---------------------------------------------------4 
College and above-----------------------------------------5 
 
Q108 Occupational status  Farmer--------------------------------------------------------1 
House wife---------------------------------------------------2 
Merchant -----------------------------------------------------3 
Employee-----------------------------------------------------4 
Others(specify)----------------------------------------------5 
 
2.  Environmental factor 
Q201 
 
 
 
 
 
Distance to ART 
center, if not know 
place 
----------------------------------------------------------in km 
 ---------------------------------------------------------place 
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 3. Psycho-social factors 
Q301 Have you told anyone 
in your families about 
your HIV status 
Yes----------------------------------------------------------1 
No-----------------------------------------------------------2 
 
Q302 Have you get any 
emotional support 
Yes----------------------------------------------------------1 
No------------------------------------------------------------2 
 
          304 
Q303 If yes, to Q 302 from 
whom you get? 
Family members-----------------------------------------1 
Friends-----------------------------------------------------2 
Both(1and 2)---------------------------------------------3 
Others(specify)------------------------------------------4 
 
Q304 Have you get any 
practical  support  
Yes-------------------------------------------------------------1 
No--------------------------------------------------------------2 
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Q305 If yes, to Q304 from 
whom you get? 
Family members----------------------------------------1 
Friends----------------------------------------------------2 
Both(1and 2)---------------------------------------------3 
Others(specify)------------------------------------------4 
 
Q306 What type of practical 
support did you get from 
your supporter 
Financial------------------------------------------------------1 
Food-----------------------------------------------------------2 
Both -----------------------------------------------------------3 
Other(specify)-----------------------------------------------4 
 
Q307 How You agree with 
the use(advantage) of 
ART  
Strongly disagree---------------------------------------1 
Disagree--------------------------------------------------2 
Undecided------------------------------------------------3 
Agree------------------------------------------------------4 
Strongly agree-------------------------------------------5 
 
4.Patient-care provider relation ship 
Q401 How do you agree 
with the trust of your 
care provider 
Strongly disagree-------------------------------------1 
Disagree------------------------------------------------2 
Undecided----------------------------------------------3 
Agree----------------------------------------------------4 
Strongly agree-----------------------------------------5 
 
Q402 How satisfied with the 
care provided 
Very dissatisfied---------------------------------------1 
Dissatisfied---------------------------------------------2 
Medium -------------------------------------------------3  
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Satisfied-------------------------------------------------4 
Very satisfied-------------------------------------------5 
 5. Nutritional factors 
Q501 Weight ----------------------------------------------------kilogram  
Q 502 Height -------------------------------------------------------meter  
Q503 
MUAC (for pregnant 
only)  
-------------------------------------------------centimeter  
Q504 
Are you receiving 
supportive foods 
(plump nut) from ART 
clinic 
Yes---------------------------------------------------------1 
No----------------------------------------------------------2 
 
Q505. 24 hour Food recall tool(list in each column) 
Breakfast Lunch Snack Dinner 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Dietary diversity (Fill in the food groups based on the above recorded).  
Millet, Sorghum 
Maize, rice, or  
other grains (beside general ration)                                cereals  1 
Pumpkin, carrots, 
squash 
sweet potatoes, 
green pepper, tomato                                                      vegetables 2 
Orange, papaya,  
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Mango and banana                                                         fruits                                                 3 
liver, kidney, heart or 
other organ meats or  
blood -based food                                                         Organ meat (iron-rich)                       4 
Beef, lamb, 
goat, chicken                                                                 flesh meat                                         5 
eggs eggs                                                  6 
Fish and sea foods                                                       fish and sea foods                             7 
beans,  peas,  lentils,  nuts,                                          legumes, nuts and seeds                  8 
seeds  or 
foods  made  from these 
milk, cheese, yogurt or 
other milk products                                                       milk and milk products                        9 
oil, fats or 
butter added to food or 
used for cooking                                                           oils and fats                                       10 
sugar, honey, sweetened  soda or 
sugary foods such as 
chocolates,                                                                 sweets                                               11 
sweets or 
candies 
sauces, coffee, 
 tea, beverage                                                     Spices, Condiments, Beverages                12 
6. Behavioral factors 
Q601 Have you ever used 
alcohol? 
Yes --------------------------------------------------1 
No ---------------------------------------------------2 
 
Q602 Are you currently 
drinking alcohol? 
Yes --------------------------------------------------1 
No ---------------------------------------------------2 
 
Q603 Have you ever 
smoked cigarette? 
Yes --------------------------------------------------1 
No ---------------------------------------------------2 
 
Q604 Are you currently 
smoking cigarette? 
Yes --------------------------------------------------1 
No ---------------------------------------------------2 
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Q605 Have you ever used 
chat? 
Yes --------------------------------------------------1 
No ---------------------------------------------------2 
 
Q606 Are you currently 
chewing chat? 
Yes --------------------------------------------------1 
No ---------------------------------------------------2 
 
7.  Medication(treatment) related factors  
Q701 When did you start 
ART? 
--------------/-----------------/-------------(date/ 
month/year) 
 
Q702 What type of ART 
regimen you had 
started? 
1a(D4t+3TC+EFV)-------------------------------1 
1b(D4T+3TC+NVP)------------------------------2 
1c(AZT+3TC+NVP)------------------------------3 
1d(AZT+3TC+EFV)-------------------------------4 
1e(TDF+3TC+EFV)-------------------------------5 
1f(TDF+3TC+NVP)-------------------------------6 
AZT+3TC+Kaletra---------------------------------7 
AzT+3TC+ABC------------------------------------8 
TDF+3TC+Kaletra--------------------------------9 
Others(specify)-----------------------------------10 
 
Q703 Did your ART 
regimen ever 
changed? 
Yes----------------------------------------------------1 
No------------------------------------------------------2           
 
           706 
Q704 If yes, to Q703 to 
what regimen it was 
changed to? 
1a(D4t+3TC+EFV)----------------------------------1 
1b(D4T+3TC+NVP)---------------------------------2 
1c(AZT+3TC+NVP)---------------------------------3 
1d(AZT+3TC+EFV)---------------------------------4 
1e(TDF+3TC+EFV)---------------------------------5 
1f(TDF+3TC+NVP)---------------------------------6 
AZT+3TC+Kaletra-----------------------------------7 
AzT+3TC+ABC---------------------------------------8 
TDF+3TC+Kaletra-----------------------------------9 
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Others(specify)--------------------------------------10 
 
Q705 If yes, to Q703 what 
was the reason for 
change? 
No improvement-------------------------------------1 
Side effect---------------------------------------------2 
Treatment failure------------------------------------3 
Other(specify)----------------------------------------4 
 
Q706 What is your current 
ART regimen? 
1a(D4t+3TC+EFV)----------------------------------1 
1b(D4T+3TC+NVP)---------------------------------2 
1c(AZT+3TC+NVP)---------------------------------3 
1d(AZT+3TC+EFV)---------------------------------4 
1e(TDF+3TC+EFV)---------------------------------5 
1f(TDF+3TC+NVP)---------------------------------6 
AZT+3TC+Kaletra-----------------------------------7 
AzT+3TC+ABC---------------------------------------8 
TDF+3TC+Kaletra-----------------------------------9 
Others(specify)--------------------------------------10 
 
Q707 What is your current 
ART follow up time? 
Every month----------------------------------------------1 
Every two month----------------------------------------2 
Every three month--------------------------------------3 
Unscheduled --------------------------------------------4 
Other (specify)-------------------------------------------5 
 
Q708 How many times you 
are taking your ART 
drugs per day? 
 
------------------------------------------------------------- 
 
Q709 How many pills you 
are taking/day? 
     
--------------------------------------------------------------- 
 
Q710 Was there any side 
effect occurred? 
Yes--------------------------------------------------------1 
No ---------------------------------------------------------2 
 
           712 
Q711 If yes to Q710, what 
type of side effect? 
Multiple responses 
are possible. 
Headache-----------------------------------------------1 
Feeling dizzy or lightheaded-----------------------2 
Skin rash------------------------------------------------3 
Itching----------------------------------------------------4 
yellow eyes---------------------------------------------5 
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Difficulty falling or staying  asleep----------------6 
 joint pain-----------------------------------------------7 
vomiting------------------------------------------------8 
others(specify)---------------------------------------9 
Q712 Have you ever 
missed any of your 
ART drugs? 
Yes------------------------------------------------------1 
No-------------------------------------------------------2 
 
           716 
Q713 If yes to, Q712 when 
was the last time you 
missed taking any of 
your ART medications? 
Within the past week---------------------------------1 
Two  weeks ago---------------------------------------2 
Three weeks ago--------------------------------------3 
Four  weeks ago--------------------------------------4 
 
Q714 What was the total 
number of pills 
missed 
 
----------------------------------------------------------- 
 
Q715 What were the reasons 
for missing? 
Multiple responses are 
possible. 
  
Away from home--------------------------------------1 
Simply forgot ------------------------------------------2 
Had too many pills to take--------------------------3 
Fear of side effect------------------------------------4 
Used alcohol-------------------------------------------5 
Felt well-------------------------------------------------6 
Lack of food to take drug---------------------------7 
Too sick-------------------------------------------------8 
Fear of disclosure------------------------------------9 
Lack of transportation cost—---------------------10 
Others(specify)--------------------------------------11 
 
 
Q716 
 
Did you use any aid 
to remember to take 
your ART drug? 
 
Yes------------------------------------------------------1 
No ------------------------------------------------------2 
 
            
           801               
Q717 If yes to 716, what 
type? 
Multiple responses 
are possible. 
Pill box------------------------------------------------1 
Written schedule------------------------------------2 
Watch bell--------------------------------------------3 
Radio bell--------------------------------------------4 
Mobile alarm-----------------------------------------5 
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Other(specify)---------------------------------------6 
8. Clinical factors 
Q801 What was your cd4 count? Base line(at time of ART start)---------------------  
Q802 Current cd4 count   
Q803 How do you follow up for 
cd4 count? 
Every three month-------------------------------------1 
Every six month----------------------------------------2 
Every year-----------------------------------------------3 
Unscheduled-------------------------------------------4 
Other(specify)------------------------------------------5 
 
Q804  What was your WHO 
staging at start of ART? 
Stage I----------------------------------------------------1 
Stage II----------------------------------------------------2 
Stage III---------------------------------------------------3 
Stage IV---------------------------------------------------4 
 
Q805 What is your  current WHO 
staging? 
Stage I-----------------------------------------------------1 
Stage II----------------------------------------------------2 
Stage III---------------------------------------------------3 
Stage IV---------------------------------------------------4 
t-stage I----------------------------------------------------5 
t-stage II---------------------------------------------------6 
t-stage III--------------------------------------------------7 
t-stage IV--------------------------------------------------8 
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Annex IV: Information sheet (Amharic version) 
              ሇተሳታፍዎች መረጃ መስጫ ቅጽ 
uቴú Ÿ}T Ö?“ ›Övup ×u=Á uì[-›?‹ ›Ãy= I¡U“ ¡õM °ÉT@Á†¬ 18 ¯Sƒ“ Ÿ²=Á uLÃ uJ’< ¾ì[-›?‹ ›Ãy= SÉH’>ƒ }ÖnT>­‹ 
eKSÉH’>ƒ ›¨dcÉ Å[Í“ }ÁÁ»’ƒ ÁK†¬” Ñ<ÇÄ‹ KT¨p KT>Å[Ó Ø“ƒ¾S[Í SeÝ pê. 
ª“ }S^T]: Å’k Åeታ• 
›T"]-‹: እÏÑ< Ñu¾ 
          ¨`nÑ–¬ GÃK< 
¾}sS< eU: Ô”Å` ¿’>y`e+ I¡U““ Ö?“ dÃ”e ¢K?Ï ¾¬eØ Ç« I¡U“ ¡õM 
SÓu=Á 
ÃI ¾Tw^`Á eUU’ƒ pê ›G<” እ`e- እ”Éd}ñuƒ ¾U”ÖÃk­ƒ” ¾U`U` ›Ã’ƒ Ø“ƒ ¾T>Áw^^ ’¬::·v¡­” u²=I Ø“ƒ KSd}õ ŸS-c”- 
uòƒ ÃI” pê S[Í cwdu=­‡ uT>Á’wKAƒ Ñ>²? uØ”no uTÇSØ ØÁo­‹ "K<­ƒ ÃÖÃl:: 
u²=I Ø“ƒ KSd}õ ŸËS\ በኋሊ uT”–¬U Ñ>²? ØÁo­‹ "K<­ƒ SÖ¾p Ã‹LK<:: 
¾Ø“~ ¯LT: 
¾²=I Ø“ƒ ¯LT uቴú Ö?“ ×u=Á ¾ì[-›?‹ ›Ãy= SÉH’>ƒ }ÖnT>­‹ eKSÉH’>ƒ ›¨dcÉ Å[Í“ }ÁÁ»’ƒ ÁK†¬” Ñ<ÇÄ‹ KT¨p“ I¡U“¬” 
KTÖ“Ÿ` ’¨<:: ÃI Ø“ƒ ¾SõƒH@ eM„‹” KSk¾e Ã[ÇM::    
¾›W^` IÅƒ 
uቴú Ÿ}T Ö?“ ›Övup ×u=Á uì[-›?‹ ›Ãy= ¡õM °ÉT@Á†¬ 18 ¯Sƒ“ Ÿ²=Á uLÃ uJ’< ¾ì[-›?‹ ›Ãy= SÉH’>ƒ }ÖnT>­‹ 
eKSÉH’>ƒ ›¨dcÉ Å[Í“ }ÁÁ»’ƒ ÁK†¬” Ñ<ÇÄ‹ KT¨p uT>"H@Å¬ Ø“ƒ ·`e-U  ·”Éd}ñ Òw²”­}M::u²=I Ø“ƒ ¬eØ KSd}õ 
Ÿ}eTS< eUU’ƒ­” SÓKê ÃÖupx}M::eU>­” S“Ñ` ›ÁeðMÓ­ƒU:: ¾T>cÖ<ƒ S[Í T>eØ^¨<’~ ¾}Öuk ’¬:: 
›ÅÒ­‹ ¨ÃU ›KSS‰†ƒ 
u²=I Ø“ƒ uSd}õ- ¾}¨c’ ÁKSS‰†ƒ eT@ƒ McS­ƒ Ã‹LM:: u}LÃ ¾Y^ Ñ>²?­ƒ” K}¨c’ Åpn ÁIM MhT Ã‹LM:: ’Ñ` Ó” Ø“~ 
ŸT>cÖ¬ ØpU ›”ì` ·”Éd}ñ }eó ·“Å`ÒK”:: 
ÖkT@ታ 
u²=I Ø“ƒ LÃ uSd}õ kØ}— ¾J’ ØpU LÁÑ–< Ã‹LK<:: ’Ñ` Ó” °`e­” u}SKŸ}¬ ¾ì[-›?‹ ›Ãy= SÉH’>ƒ ›ÖnkU“ ¬Ö?ƒ u`"} c­‹ 
}ÖnT> ÃJ“K<:: 
¾}dƒö ¡õÁ­‹ 
uØ“~ uSd}õ- ¾T>cØ ¡õÁ ¾KU 
T>eØ` eKSÖup 
u²=I Ø“ƒ ¾T>cucu¬ S[Í uT>eØ` ÃÖunM&& ¾T>cucu¬ SÖÃp ¾°`e- KSJ’< SKÁ ›Ã•[¬U&&S[Í¬ uª“ }S^T]¬ ðÃM 
}Å`Ô ulMõ ¾T>kSØ uSJ’< K?L c¬ K=ÁÑ–¬ ›Ã‹MU&& 
uØ“~ ÁKSd}õ ¨ÃU ^e­” ŸØ“~ ¾TÓKM Swƒ 
uØ“~ LKSd}õ ŸðKÑ< u²=I Ø“ƒ ÁKSd}õ S<K< Swƒ ›K­ƒ&& ŸSÖÃl ¬eØ Ømƒ -ÃU S<K< uS<K< ØÁo­‹” ÁKSSKe 
Ã‹LK<&& 
¾T>ÁÑ–<›†¬ c­‹/}Ö`­‹ 
K²=I Ø“ƒ T’ÒÑ` ŸðKÑ< ŸT>Ÿ}K<ƒ ¬eØ ¾ðKÑ<ƒ” T’ÒÑ` Ã‹LK<&& 
        1. Å’k Åeታ          eM¡ lØ`. 0935663303 
        2. ›„ እÏÑ< Ñu¾ 
        3. Ê/` ¨`nÑ–¬ GÃK< 
  
AnnexV: Consent form Amharic(የስምምነት ቅጽ) 
 
  
                                                                                                                   ቀን----------------------- 
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በቴፒ ጤና ጣቢያ በፀረ-ኤች አይ ቪ ህክምና ክፍሌ ዕዴሜያቸዉ 18 እና ከዚያ በሊይ በሆኑ የመዴሃኒቱ ተጠቃሚዎች ሊይኤች አይቪ 
ኤዴስ ህክምና ትክክሇኛ አወሳሰዴ ሁኔታን ሇማወቅና በአወሳሰደ ጊዜ  የሚያጋጥሙ ችግሮችን ሇይቶ ሇማወቅ በሚሌ ጥናታዊ ጽሁፍ 
ሊይ እንዴሳተፍ ስጠየቅ ስሇጥናቱ ዓሊማና ይዘት እንዴያዉቀዉ የተዯረገ ሲሆን በማንኛዉም ጊዜ ከጥናቱ ራሴን ማግሇሌ እንዯምችሌ 
ስሇተገሇፀሌኝ በጥናቱ ሇመሳተፍ ሙለ ፍቃዯኛ መሆኔን እገሌፀሇሁ፡፡ በተጨማሪ ሇሚጠይቁት ጥያቄ ፍቃዯኛ መሆኔን በፍርማዬ 
አረጋግጣሇሁ፡፡ 
 
የተሳታፍ ፍርማ----------------------------------- ቀን----------------------------- 
የመረጃ ሰብሳቢ ፍርማ-----------------------------ቀን-----------------------------    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annex VI: questionnaires (Amharic version) 
በጎንዯር ዩኒቨርሲቲ ህክምናና ጤና ሳይንስ ኮላጅ የዉስጥ ዲዌ ህክምና ትምህርት ክፍሌ 
የፀረ ኤች አይ ቭ መዴሃኒት በመዉሰዴ ሊይ ያለ ኤች አይቪ ኤዴስ ህሙማን ስሇመዴሃኒቱ አወሳሰዴ ሁኔታ ሇማጥናት የቀረበ 
መጠይቅ 
ቀን----------------------------------ቃሇመጠይቅ አዴራጊዉ ስም---------------------------------------ፍርማ------------------ 
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የሱፐርቫይዘሩ ስም--------------------------------------------------------------------------------------ፍርማ------------------ 
እኔ ስሜ----------------------------------------ይባሊሌ፡፡ የጎንዯር ዩኒቨርሲቲየዉስጥ ዲዌ ህክምና ትምህርት ክፍሌ የፀረ ኤች አይ ቭ 
/ኤዴስ መዴሃኒትአወሳሰዴ ሁኔታና በአወሳሰደ ጊዜ የሚያጋጥሙ ችግሮችን ሇይቶ ሇማወቅ ጥናት እያካሄዯ ነዉ፡፡በአሁኑ ሰዓት በቴፒ 
ጤና ጣቢያ  በፀረ ኤች አይ ቭ /ኤዴስ መዴሃኒትአወሳሰዴ ሊይ ተፅህኖ  የሚያዯርሱ ነገሮችን ሇመሇየት በሚዯረገዉ ጥናት መረጃ 
እየሰበሰብኩ እገኛሇሁ፡፡በዚህ ጤና ጣቢያ ህክምና ከሚከታተለት መካከሌ ሇጥናቱ የተወሰኑትን በመምረጥ ሲጋብዝ እርስዎን 
ጋብዟሌ፡፡  
የጥናቱ ዋና ዓሊማ የፀረ ኤች አይቪ ኤዴስ ህክምና ትክክሇኛ አወሳሰዴ ሁኔታን ሇማወቅና በአወሳሰደ ጊዜ  የሚያጋጥሙ ችግሮችን 
ሇይቶ ሇማወቅና መፍትሄ ሇመፈሇግ ነዉ፡፡ ይህ ዯግሞ ሇወዯፍት ዕቅዴ ሇመሥራትና መፍትሄዉንም ሇማስቀመጥ አስፈሊጊ የሚሆኑ 
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የምበሊወ ምግብ ስሇሇሇኝ---------------------------------7 
ህመሙ ሰሇጠናብኝ--------------------------------------8 
መዴሃኒት መውሰዳን እንዲያውቁብኝ ፈረቼ --------------9 
የመገገዣ ገንዘብ ስሇላሇኝ —--------------------------10 
ላሊ ካሇ ይጥቀሱ --------------------------------------11 
 
716 ምዴሃኒቱን ሇመውስዴ ሚያግዝ 
ማስታዎሻ ዘዳዎችን ይጠቀማለ 
 አዎን------------------------------------------------------1 
የሇም ------------------------------------------------------2 
 
     801 
717 ከሊይ በተራ ቁጠር 716 ሇተጠቀሰው 
ጥያቄ አዎን ከሆነ መሌሰዎ፣ 
ከሚከተለት የትኞቹን ይጠቀማለ?  
የእንክብሌ ሳጥን------------------------------------------1 
የጹሁፍ ማስታዎሻ ---------------------------------------2 
የሰዓት መጥሪያ ዯዎሌ-------------------------------------3 
የሪዱዩ መጥሪያ ዯወሌ-------------------------------------4 
 የሞባይሌ መጥሪያ ዯወሌ ---------------------------------5 
 ላሊ ካሇ ይጠቀስ -----------------------------------------6 
 
801 የcd4 መጠን ስንት ነዉ መዴሃኒቱን ስጀምሩ------------------------------------------- 
የቅርብ ጊዜ-------------------------------- 
 
802 cd4 የሚሇኩበት ቀጠሮ ጊዜ 
እንዳት ነዉ 
በየሶስት ወር-------------------------------------------------------------1 
በየስዴስት ወር-----------------------------------------------------------2 
በየዓመቱ-----------------------------------------------------------------3 
የጊዜ ቀጠሮ የሇም-------------------------------------------------------4 
ላሊ (ጥቀስ)-------------------------------------------------------------5 
 
803 መዴሃኒቱን ስጀሚሩ ተጓዲኝ ህመም 
ነበረብዎት 
አዎን---------------------------------------------------------------------1 
የሇም---------------------------------------------------------------------2 
 
     805 
804 መሌስዎ ሇጥያቄ 803 አዎን ከሆነ፣ 
የህመሙ ዯረጃ ስንት ነዉ 
ዯረጃ አንዴ-------------------------------------------------------------1 
ዯረጃ ሁሇት-------------------------------------------------------------2 
ዯረጃ ሶስት---------------------------------------------------------------3 
ዯረጃ አራት-------------------------------------------------------------4 
 
Q805 በቅርብ ጊዜ ተጓዲኝ ህመም 
ነበረብዎት 
አዎን---------------------------------------------------------------------1 
የሇም---------------------------------------------------------------------2 
 
    ÁlS< 
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Q806 መሌስዎ ሇጥያቄ 805 አዎን ከሆነ፣ 
የህመሙ ዯረጃ ስንት ነዉ 
ዯረጃ አንዴ-------------------------------------------------------------1 
ዯረጃ ሁሇት-------------------------------------------------------------2 
ዯረጃ ሶስት---------------------------------------------------------------3 
ዯረጃ አራት-------------------------------------------------------------4 
 
 
 
                                                                     መጠይቁን ስንሞሊ ሰሇተባበሩን በጣም እናመሰግናሇን!!. 
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